iSRS 2023 Presymposium Workshop 1

• Radiofluorination - A long journey reviewed
• State of the art in copper-mediated radiofluorinations of organoboranes
• Pretargeting: Performing radiolabelling in vivo and “tricking” slow pharmacokinetics
• Click for PET (Part II): Dos and don’ts of [18F]SuFEx click chemistry at a glance

iSRS 2023 Presymposium Workshop 2

• ABC of computer-aided radiotracer design, Johanna Steen
• In silico approaches for CNS PET Tracer Design, Peter Scott
• AI in chemistry, with focus on data-driven reaction prediction, Teodoro Laino
• Hands-on workshop, Teodoro Laino

iSRS 2023 Presymposium Workshop 3

• Introduction and welcome
• Radionuclide Production and Radiochemistry, Tara Mastren
• Chelation and Synthesis of Radiopharmaceuticals, Caterina Ramogida
• Pre-clinical Translation of Radiopharmaceuticals, Danielle Vugts
• Clinical Translation of Radiopharmaceuticals, Lisa Bodei
• Discussions and questions to panelists from audience

iSRS  2023 Keynote 1 & Opening Ceremony

• Keynote 1, Lisa Bodei: Theranostics, Here Comes the Sun
• Opening Ceremony

iSRS 2023 Keynote 2 & Scientific Session 1

• Keynote 2, Imaging to Improve Cancer Nanomedicine Clinical Translation, Twan Lammers
• (O-01) Mannose Receptor (CD206) Targeting with Aluminum Fluoride-18 Labeled Mannosylated Dextran
• (O-02) Evaluation of the combinationally glycated albumin nanoplatform for targeting the tumor microenvironment with minimized reticuloendothelial system uptake using PET imaging
• (O-03) ¹³¹I-urease nanomotors as potential radiotherapeutic agents for bladder cancer
• (O-04) StarPEG Nanocarriers for PSMA Targeted Radioligand Imaging and Therapy

iSRS 2023 Scientific Session  2

• (O-05) Development of [^18F]Fluoromannitol, a Novel Radiopharmaceutical for Infection Imaging
• (O-06) Evaluation of tetramethylammonium salts in minimalist-like S_NAr radiofluorinations
• (O-07) Radiofluorination of Sterically Hindered Amides: Automation, Stability Studies, and Mechanism
• (O-08) Photoredox-assisted ¹⁸F-radiodeoxyfluorination of diaryl ethers favors the more electron-rich aryl group
• (O-09) Development of a (+)RESCA-triaryl phosphine for in vitro radiolabeling using the Staudinger ligation
• (O-10 )Development of ¹⁸F-Labelled CXCR4-Targeted Peptide Radiopharmaceuticals Through Strain-Promoted Click Chemistry

iSRS 2023 Scientific Session 3

• (O-12) Exploring a Tristhione Scorpionate Ligand as a Suitable Chelator for the Theranostic Pair Antimony-119 and Antimony-117
• (O-13) Triaza-18-Crown-6 Macrocycle Scaffold: Chelator Platform for Theranostic Application
• (O-14) Evaluation of ¹³⁴Ce/La pair as a PET imaging surrogate for ²²⁵Ac radiotherapeutics
• (O-15) Complexation of [¹⁸⁶Re][Re(CO)3]+ and [^99mTc][Tc(CO)3]+ cores with TACN-based chelators
• (O-16) The chelate makes the difference: Positively charged copper complexes favor receptor affinity and cell internalization of gastrin-releasing peptide receptor agonists and antagonists

iSRS 2023 Scientific Session 4 and Rapid-Fire 1

• (O-17) TRIGA Reactor Production and Synergistic Separation of ¹⁶¹Tb from Enriched ¹⁶⁰Gd Targets Using Novel Extraction Chromatographic Resins
• (O-18) Improvements in separation of antimony-119 from bulk tin target using a novel dibutyl ether resin
• (O-19) Auger electrons in radionuclide therapy: Szilárd-Chalmers effect / hot atom chemistry during the targeted delivery of the isotopes
• (O-20) High radiochemical yield and molar activity ⁵²gMn from electroplated chromium
• (O-21) Scale up production and purification of high specific activity lead-203 (²⁰³Pb)
• (RF-01) Design and synthesis of fluorinated pyrazolidine-3,5-dione derivatives as potential P2Y₁₂ receptor PET tracers
• (RF-02) Development of a novel Azabenzimidazoles-Based PET radioligands for γ-8 dependent transmembrane AMPA receptor regulatory protein imaging
• (RF-03) The evaluation of enzyme-mediated forms of [¹⁸F]AlF-RESCA-VHH5v2 exemplified with human CD8 PET imaging
• (RF-04) Radiation-induced DNA Damage and Repair in Targeted Radionuclide Therapies in Comparison to External Beam Radiation (RF-04)
• (RF-05) Radiolabeling of two different precursors of m-[²¹¹At]astatobenzylguanidine using ²¹¹At purified by wet extraction.
• (RF-07) A novel ¹⁸F-labeled reversible PET ligand for imaging monoacylglycerol lipase
• (RF-08) Dual labelling platform for theranostics: PSMA-targeted imaging with ^99mTc and therapy with ¹⁸⁸Re

iSRS 2023 Scientific Session 5

• (O-22) [¹¹C]HSP990 PET as a translational tool to investigate the aberrant role of Hsp90 in tumors and support the development of Hsp90 therapeutics
• (O-23) Development of an ¹⁸F-labeled MutT Homolog 1 (MTH1) radiotracer ([¹⁸F]WC-7-73): synthesis, radiosynthesis and evaluation
• (O-25) PET Imaging of Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68

iSRS 2023 Scientific Session 6

• (O-26) Combining Positron Emission Tomography and Hyperpolarized Magnetic Resonance to Interrogate Prostate Cancer Metabolism
• (O-27) A kit-based approach to aluminium-[¹⁸F]fluoride-labelled microbubbles and their in vivo biodistribution following ultrasound-targeted microbubble destruction
• (O-28) Proof-of-concept optimization of copper-mediated radiosynthesis of [¹⁸F]FBnTP using a novel automated robotic high-throughput droplet radiochemistry system
• (O-29) Development of Approaches for High-Throughput Experimentation in Radiochemistry
• (O-30) Assessing the binding affinity of a ⁶⁴Cu-labeled PSMA ligand in a micro physiological system
• (O-31) Introduction of terbium-161 into the clinics through its automated purification and the Good Manufacturing Practice compliant production of [¹⁶¹Tb]Tb-DOTA-LM3

iSRS 2023 Scientific Session 7

• (O-32) Ultra-fast and efficient conversion of [¹¹C]CO₂ into [11C]hydantoins via the Bucherer-Bergs multicomponent reaction.
• (O-33) Rapid and Efficient Syntheses of [¹¹C]Trifluoroethoxy Heteroarenes with a Novel ¹¹C-Labeling Synthon, [¹¹C]CF₃CH₂OK
• (O-34) Intramolecular Friedel-Crafts acylation of carbon-11 isocyanates enabling radiolabeling of [carbonyl‑¹¹C]DPQ
• (O-35) ¹¹C-guanylated histamine for PET cardiac imaging
• (O-36) Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Radioligand Therapy Applications

iSRS 2023 Scientific Session 8 and Rapid-Fire 2

(O-38) PET/CT Imaging of a_vb₆ Integrin to Monitor Radiation-Induced Pulmonary Fibrosis

(O-39) Non-invasive imaging of neutrophils in acute sepsis

(O-40) [¹⁸F]GP1, a novel PET tracer investigated for the detection of thrombi in LVADs and for the diagnosis of valve thrombosis

(O-41) [¹¹C]Vercirnon - a candidate PET radioligand for the CCR9 chemokine receptor

(O-42) Real-time tracking of micro- and nanoplastics in mice after pulmonary exposure

(RF-08) [¹⁸F]FLUDA – A promising PET probe for the non-invasive assessment of the A_2A adenosine receptor

(RF-09) Stabilization of ⁶⁸Ga-labeled [Thz₁₄]Bombesin(7-14) analogue for imaging gastrin-releasing peptide receptor expression with positron emission tomography

(RF-10) Identification of non-competitive lead peptides for the development of PET tracers targeting PD-L1

(RF-11) Next generation copper complexes for efficient production of radiolabeled aromatics

(RF-12) Identifying Lymph Node Metastasis in High Grade Serous Ovarian Cancer Mouse Models via ImmunoPET Imaging

(RF-13) A stable and robust production process of [¹⁸F]fluorodeprenyl-D2 using a cassette-type chemistry module

(RF-14) ⁶⁴Cu production via the ⁶⁸Zn(p,nα)⁶⁴Cu nuclear reaction: Targetry, radiochemistry and PET imaging for utility assessment

iSRS 2023 Scientific Session 9

• (O-44) Preparing Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist [¹⁸F]Ubrogepant to Enable Biodistribution Studies in Non-Human Primate
• (O-45) Synthesis and preclinical evaluation of [¹⁸F]DASA-10 a second generation PKM2 specific radiotracer
• (O-46) Novel Radiofluorination via Electrophilic Activation of Alkyl Phosphates/Phosphonate
• (O-47) 3-[¹⁸F]Fluoro-5-hydroxy- and 3-[¹⁸F]fluorophenylserines: Preparation and initial biological evaluation
• (O-48) Development of a new reagent for ¹⁸F-trifluoroethylation of secondary amine

iSRS 2023 Scientific Session 10 & 11

• (O-49) The Synthesis, DoE Optimization, and Automation of the CLIPtag Radiotracer [¹⁸F]pFBC and its Evaluation in a Murine Brain Viral Gene Transfer Model.
• (O-50) Design, synthesis, and biological evaluation of orthosteric ligands for the muscarinic acetylcholine receptors
• (O-51) Generation of ²²⁵Ac-DOTA-rituximab SPECT image from ⁶⁴Cu-DOTA-rituximab PET image using unpaired image-to-image translation
• (O-52) Application of Machine Learning Driven Computational Approaches for Novel CNS PET Tracer Development
• (O-53) Theoretical and experimental study of astatine-metal bonds: towards new ²¹¹At-labelling approaches based on transition metal complexes
• (O-54) Preclinical evaluation of [^155/161Tb]Tb-crown-TATE – a novel SPECT imaging agent targeting neuroendocrine tumors
• (O-55) Chelation of Manganese - 52 for development of long-lived PET radiopharmaceuticals
• (O-56) CD133-Targeted Radioimmunotherapy of Small Cell Lung Cancer

iSRS 2023 Scientific Session 12

• (O-57) Synthesis and translational evaluation of three novel PARP PET tracers in nonhuman primates and rodent glioma brain tumor model with intact blood-brain barrier
• (O-58) Development of [⁶⁸Ga]Ga-DOTA-4AH29, a radiolabeled single-domain antibody for PET imaging of FAP-α expression in cancer
• (O-59) Preclinical evaluation of [⁸⁹Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC)
• (O-60) Evaluating the Interplay of ⁸⁹Zr-labeled Radioimmunoconjugates and Fc Receptors in Genetically Engineered Mouse Models
• (O-61) Evaluating the effect of an albumin binder for targeting melanoma tumors with ⁸⁹Zr-Lumi804-Lys-pIBA-PEG₄-LLP2A
• (O-62) Phase I trial for SPECT imaging of GRPR expression in malignant tumors using [^99mTc]Tc-maSSS-PEG2-RM26 prepared using one-pot labeling kit

iSRS 2023 Scientific Session 13

• (O-63) ¹⁸F-labeled imidazole naphthyridine derivatives as Tau imaging agents in Alzheimer’s Disease
• (O-64) [¹⁸F]OXD-2314: A 4R-Tau PET Radiotracer with Improved Affinity and Brain Uptake
• (O-65) Enantioselective Synthesis and Biological Evaluation of (R)- and (S)-[¹⁸F]OF-NB1 to Visualize GluN2B Subunit-Containing NMDA Receptors
• (O-67) Quantitative Evaluation of a Novel PET Radioligand for the Monoacylglycerol Lipase (MAGL) in Non-Human Primates
• (O-68) Syntheses and biological evaluation of two F-18 radiotracers for imaging MLKL in the brain
• (O-69) Discovery, preclinical validation and early human imaging with [¹¹C]AZ14193391 – the first blood-brain barrier permeable and subtype selective PARP1 PET radioligand

iSRS 2023 Scientific Session 14  and Rapid-Fire 3

• (O-70) Optimization of the automated radiosynthesis of an ¹⁸F-labeled tetrahydroquinoline derivative for brain HDAC6 imaging
• (O-71) cGMP synthesis of 4-[¹⁸F]fluoro-1-naphthol, a novel PET tracer for imaging activation of innate immunity
• (O-72) Site-specifically THP-functionalized hPD-L1 single-domain antibody: preliminary data toward kit development
• (O-73) Automated cassette based synthesis of novel CB1 receptor tracer [¹⁸F]FPATPP produced via Ru-mediated ¹⁸F-fluorination
• (RF-15) Dual PET imaging of microtubule destabilization and synaptic integrity in a mouse model of AD
• (RF-16) Chemoenzymatic Synthesis of Fluorine-18-Labelled Disaccharides Used for PET Imaging of Bacteria Infection
• (RF-17) Comparison of the Biodistribution of [¹⁸F]FNP-59 and its Esters
• (RF-18) Radiosynthesis and preliminary evaluation of a novel PET probe for neuronal complement C3 activation imagingRadiosynthesis and preliminary evaluation of a novel PET probe for neuronal complement C3 activation imaging
• (RF-19) Fully Automated Production of [¹¹C]ABP688, [¹¹C]PS13, and [¹¹C]PIB Using a TracerMaker Synthesis Module for Clinical Studies
• (RF-20) The synthesis of [¹¹C]phosgene and its use in the synthesis of [2-¹¹C]thymine
• (RF-21) Chemically Identical Pair of Theranostic Small-Molecule Drug Conjugates for Prostate Cancer Imaging and Chemotherapy

iSRS 2023 Keynote 4 and Scientific Session 15 and Closing Ceremony

• Keynote 4, Theranostics with Metallic Radionuclides that Target Metalloenzymes and Immune Checkpoints, Paul Donnelly
• (O-74) Development of Terbium-161 Based VLA-4 Targeted Theranostics
• (O-75) A side-by-side comparison of a monomer- versus a dimer-based ⁶⁸Ga- and ¹⁷⁷Lu-labeled FAP inhibitor for theranostic tumor stroma targeting
• (O-76) Preclinical evaluation of ePSMA-DM1: a PSMA-targeting theranostic small molecule drug conjugate
• (O-77) Molecular imaging and radiopharmaceutical therapy of Multiple Myeloma targeting CD46 using 89Zr and 225Ac-YS5
• (O-78) Investigation of therapeutic effect, associated hypoxia and antioxidant signaling induced by copper-64 in colon carcinoma
• Closing Ceremony